282 related articles for article (PubMed ID: 29596219)
1. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis.
Tsekoura M; Ioannidou M; Pana ZD; Haidich AB; Antachopoulos C; Iosifidis E; Kolios G; Roilides E
Pediatr Infect Dis J; 2019 Jan; 38(1):42-49. PubMed ID: 29596219
[TBL] [Abstract][Full Text] [Related]
2. Echinocandins vs. amphotericin B against invasive candidiasis in children and neonates: A meta-analysis of randomized controlled trials.
Chen YH; Cheng IL; Lai CC; Tang HJ
Int J Antimicrob Agents; 2019 Jun; 53(6):789-794. PubMed ID: 30831231
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
Cornely OA; Marty FM; Stucker F; Pappas PG; Ullmann AJ
Mycoses; 2011 Nov; 54(6):e838-47. PubMed ID: 21668522
[TBL] [Abstract][Full Text] [Related]
6. Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study.
Viscoli C; Bassetti M; Castagnola E; Cesaro S; Menichetti F; Ratto S; Tascini C; Giacobbe DR
BMC Infect Dis; 2014 Dec; 14():725. PubMed ID: 25551699
[TBL] [Abstract][Full Text] [Related]
7. Echinocandin use in the neonatal intensive care unit.
Caudle KE; Inger AG; Butler DR; Rogers PD
Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
[TBL] [Abstract][Full Text] [Related]
8. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants.
Mohamed WA; Ismail M
J Trop Pediatr; 2012 Feb; 58(1):25-30. PubMed ID: 21355042
[TBL] [Abstract][Full Text] [Related]
10. A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis.
Benjamin DK; Kaufman DA; Hope WW; Smith PB; Arrieta A; Manzoni P; Kovanda LL; Lademacher C; Isaacson B; Jednachowski D; Wu C; Kaibara A; Walsh TJ
Pediatr Infect Dis J; 2018 Oct; 37(10):992-998. PubMed ID: 29596222
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
13. [Micafungin in invasive candidiasis among oncohematological patients].
Jarque I; Angel Sanz M
Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses.
Domingos EL; Vilhena RO; Santos JMMF; Fachi MM; Böger B; Adam LM; Tonin FS; Pontarolo R
Int J Antimicrob Agents; 2022 Aug; 60(2):106614. PubMed ID: 35691603
[TBL] [Abstract][Full Text] [Related]
15. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.
Blyth CC; Hale K; Palasanthiran P; O'Brien T; Bennett MH
Cochrane Database Syst Rev; 2010 Feb; 2010(2):CD006343. PubMed ID: 20166083
[TBL] [Abstract][Full Text] [Related]
16. [Why might micafungin be the drug of choice in pediatric patients?].
Ramos Amador JT; Prieto Tato L; Guillén Martín S
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
[TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of invasive neonatal candidiasis.
Botero-Calderon L; Benjamin DK; Cohen-Wolkowiez M
Expert Opin Pharmacother; 2015 May; 16(7):1035-48. PubMed ID: 25842986
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
[TBL] [Abstract][Full Text] [Related]
19. Treatment of invasive candidal infections: systematic review and meta-analysis.
Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
[TBL] [Abstract][Full Text] [Related]
20. [Drug interactions in critically-ill patients. An important factor in the use of micafungin?].
Garnacho-Montero J; Jiménez Parrilla F
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():33-7. PubMed ID: 21420575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
